| Literature DB >> 31327655 |
Wenjing Su1, Hyun Ho Han2, Yan Wang3, Boyu Zhang3, Bing Zhou4, Yuanming Cheng1, Alekya Rumandla3, Sreeharsha Gurrapu3, Goutam Chakraborty5, Jie Su6, Guangli Yang7, Xin Liang8, Guocan Wang8, Neal Rosen1, Howard I Scher9, Ouathek Ouerfelli7, Filippo G Giancotti10.
Abstract
The mechanisms that enable immune evasion at metastatic sites are poorly understood. We show that the Polycomb Repressor Complex 1 (PRC1) drives colonization of the bones and visceral organs in double-negative prostate cancer (DNPC). In vivo genetic screening identifies CCL2 as the top prometastatic gene induced by PRC1. CCL2 governs self-renewal and induces the recruitment of M2-like tumor-associated macrophages and regulatory T cells, thus coordinating metastasis initiation with immune suppression and neoangiogenesis. A catalytic inhibitor of PRC1 cooperates with immune checkpoint therapy to reverse these processes and suppress metastasis in genetically engineered mouse transplantation models of DNPC. These results reveal that PRC1 coordinates stemness with immune evasion and neoangiogenesis and point to the potential clinical utility of targeting PRC1 in DNPC.Entities:
Keywords: MDSCs; Tregs; angiogenesis; combination therapy; epigenetics; immune evasion; immune microenvironment; metastasis; preclinical compound; stemness
Mesh:
Substances:
Year: 2019 PMID: 31327655 PMCID: PMC7210785 DOI: 10.1016/j.ccell.2019.06.009
Source DB: PubMed Journal: Cancer Cell ISSN: 1535-6108 Impact factor: 31.743